Zhou Xun, Chen Hui, Li Jinqing, Shi Yingfeng, Zhuang Shougang, Liu Na
Department of Nephrology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Department of Medicine, Rhode Island Hospital and Alpert Medical School, Brown University, Providence, RI, United States.
Front Pharmacol. 2022 Apr 26;13:885527. doi: 10.3389/fphar.2022.885527. eCollection 2022.
Methylation can occur in both histones and non-histones. Key lysine and arginine methyltransferases under investigation for renal disease treatment include enhancer of zeste homolog 2 (EZH2), G9a, disruptor of telomeric silencing 1-like protein (DOT1L), and protein arginine methyltransferases (PRMT) 1 and 5. Recent studies have shown that methyltransferases expression and activity are also increased in several animal models of kidney injury, such as acute kidney injury(AKI), obstructive nephropathy, diabetic nephropathy and lupus nephritis. The inhibition of most methyltransferases can attenuate kidney injury, while the role of methyltransferase in different animal models remains controversial. In this article, we summarize the role and mechanism of lysine methyltransferase and arginine methyltransferase in various kidney diseases and highlight methyltransferase as a potential therapeutic target for kidney diseases.
甲基化可发生在组蛋白和非组蛋白中。正在研究用于肾脏疾病治疗的关键赖氨酸和精氨酸甲基转移酶包括zeste同源物2增强子（EZH2）、G9a、端粒沉默破坏因子1样蛋白（DOT1L）以及蛋白精氨酸甲基转移酶（PRMT）1和5。最近的研究表明，在几种肾脏损伤的动物模型中，如急性肾损伤（AKI）、梗阻性肾病、糖尿病肾病和狼疮性肾炎，甲基转移酶的表达和活性也会增加。大多数甲基转移酶的抑制可减轻肾脏损伤，而甲基转移酶在不同动物模型中的作用仍存在争议。在本文中，我们总结了赖氨酸甲基转移酶和精氨酸甲基转移酶在各种肾脏疾病中的作用和机制，并强调甲基转移酶作为肾脏疾病潜在治疗靶点的地位。
